Discussion
Top-line results — a snapshot of key early findings — from a large international clinical trial testing Immunovant’s therapy candidate IMVT-1402 in adults with generalized myasthenia gravis (gMG) are expected next year, according to the developer. The trial, involving an estimated 231 participants at 88 locations worldwide, is…
